Long‐term quantitative hepatitis B surface antigen (HBsAg ) trajectories in persons with and without HBsAg loss on tenofovir‐containing antiretroviral therapy
Year: 2023
Type: article
Study design: Observational Study
Abstract: Objectives Improving the understanding of the patterns of quantitative hepatitis B surface antigen (qHBsAg) trajectories associated with HBsAg loss is important in light of novel anti‐hepatitis B virus agents being developed. We evaluated long‐term qHBsAg trajectories in persons with HIV and HBV during tenofovir‐containing antiretroviral therapy in the Swiss HIV Cohort Study. Methods We included 29 participants with and 29 without HBsAg loss, defined as qHBsAg <0.05 IU/mL. We assessed qHBsAg decline during therapy in both groups and used agglomerative hierarchical clustering to identify different qHBsAg trajectory profiles in persons with HBsAg loss. Results The median follow‐up time was 11.9 years (IQR 8.4–14.1), and the median time to HBsAg loss was 48 months (IQR 12–96). Among participants with HBsAg loss, 79% had a qHBsAg decline ≥1 log10 IU/mL 2 years after starting tenofovir. The trajectories in qHBsAg levels during tenofovir therapy were heterogeneous, characterized by five distinct profiles. Among participants without HBsAg loss, only 7% had a qHBsAg decline ≥1 log10 IU/ml after 2 years. Conclusions Most persons with HIV who experienced HBsAg loss had an early decline in qHBsAg levels, with diverse trajectories during long‐term tenofovir therapy. In persons without HBsAg loss, qHBsAg levels remained remarkably stable over time.
Source: HIV Medicine
DOI: 10.1111/hiv.13561
Authors: Lorin Begré, Anders Boyd, Luisa Salazar‐Vizcaya, Franziska Suter‐Riniker, Charles Béguelin, Jürgen K. Rockstroh, Huldrych F. Günthard, Alexandra Calmy, Matthias Cavassini, Marcel Stöckle, Patrick Schmid, Enos Bernasconi, Massimo Levrero, Fabien Zoulim, Gilles Wandeler, Andri Rauch, the Swiss HIV Cohort Study (SHCS)
Institutions: University of Bern, University Hospital of Bern, Stichting HIV Monitoring, GGD Amsterdam, University Hospital Bonn, University of Zurich, University Hospital Zurich, University of Geneva, University Hospital of Geneva, Centre Hospitalier Universitaire Vaudois, University of Lausanne, University of Basel, University Hospital of Basel, Kantonsspital St. Gallen, Ospedale regionale di Lugano, Università della Svizzera italiana, Lyon 1 Université, Centre National de la Recherche Scientifique, Inserm, Hospices Civils de Lyon, Centre de Recherche en Cancérologie de Lyon
Language: English
Topic: Hepatitis B Virus Studies
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,760
Funders: National Science Foundation, Gilead Sciences, Inselspital, Universitätsspital Bern, European Commission, Agence Nationale de la Recherche, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Schweizerische Akademie der Medizinischen Wissenschaften, Swiss HIV Cohort Research Foundation, Horizon 2020 Framework Programme
Awards: Swiss HIV Cohort Study, G3105035837, G3640015396, Quantitation of circulating viral RNAs as a new biomaker of Hepatitis B functional cure, G4937468798, G495187929, G5411684512, G6687241368, G6803667113, Functional cure of hepatitis B in Switzerland and sub-Saharan Africa: determinants and long-term impact on clinical outcomes, Immune profiling to guide host-directed interventions to cure HBV infections
OpenAlex ID: W4387515924